Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Trial details
- Registry ID
- NCT07011719
- Drugs studied
- Cabozantinib, Casdatifan
TrialRedline tracks 6 clinical trials sponsored by Arcus Biosciences, Inc.: 3 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaNCT07011719 | Cabozantinib, Casdatifan | Recruiting | 2028-04Estimated |
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT06608927 | Gemcitabine, Nab-paclitaxel, Quemliclustat | Active not recruiting | 2030-11-30Estimated |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095 | Capecitabine, Domvanalimab, Fluorouracil, Leucovorin and 3 more | Completed | 2026-08-28Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | Carboplatin, Domvanalimab, Paclitaxel, Pembrolizumab and 2 more | Completed | 2026-09-17Actual |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 | Domvanalimab, Fluorouracil, Leucovorin, Oxaliplatin and 2 more | Completed | 2026-09-07Actual |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856 | Domvanalimab, Etrumadenant, Zimberelimab | Completed | 2025-07-09Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: Jan 2027. After: 7 Sep 2026.
Before: Active not recruiting. After: Completed.
NCT04736173 · Arcus Biosciences, Inc.
Before: Estimated. After: Actual.
Before: May 2027. After: 17 Sep 2026.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Aug 2026. After: 28 Aug 2026.
Before: Active not recruiting. After: Completed.
Before: Jun 2026. After: Aug 2026.
NCT04262856 · Arcus Biosciences, Inc.
Before: 5 Jun 2025. After: 9 Jul 2025.